Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results topping the market’s revenue expectations, with ...

Pfizer (NYSE: PFE) posted adjusted earnings per share of $0.63 for Q4, exceeding the analyst consensus of $0.48. Revenue came ...

Pfizer beats Q4 estimates with 24.9% revenue growth, reaffirming 2025 guidance and targeting $4.5 billion in cost savings ...

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

US pharma giant Pfizer reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial ...

Pfizer Inc. (NYSE: PFE) reported a strong performance for the fourth quarter of 2024, with revenues reaching $17.8 billion.

BRAFTOVI's FDA Approval Sparks Hope for BRAF V600E-mutant Colorectal Cancer Patients and Sets Pfizer Up for Explosive Growth ...

Strong Covid product sales and cost-cutting initiatives drove Pfizer's $17.76 billion in revenue in Q4, exceeding Wall Street ...

Pfizer ( PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...